JJJakob Kristian Jakobsen

Jakob Kristian Jakobsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jakob Kristian Jakobsen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • DaPeCa‐3: promising results of sentinel node biopsy combined with 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node‐negative patients with penile cancer – a national study from Denmark

    by Jakob Kristian Jakobsen, Louise Alslev, Pia Ipsen, Junia Cardoso Costa, Kim Predbjørn Krarup, Peter Sommer, Henrik Nerstrøm, Birgitte Grønkær Toft, Søren Høyer, Kirsten Bouchelouche, et al.

    Objectives: To estimate the diagnostic accuracy of sentinel node biopsy ( SNB ) combined with preoperative 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography ( FDG PET / CT ) for inguinal lymph node ( LN ) evaluation in patients with invasive penile squamous cell carcinoma ( PSCC ) with no clinical evidence of inguinal metastases ( cN 0) at two tertiary centres with complete clinical follow‐up. Patients and Methods: From April 2010 in Centre one and from January 2013 in Centre two, we prospectively enrolled patients diagnosed with invasive PSCC and scheduled for SNB at the only two university centres treating penile cancer in Denmark. All patients had FDG PET / CT before SNB . The sentinel LN s were preoperatively located by planar lymphoscintigraphy in 134 groins (68 patients) and by single‐photon emission CT / CT in 120 groins (61 patients). The primary endpoints were the sensitivity, specificity, and false‐negative rate of SNB combined with FDG PET / CT . The secondary endpoint was SNB ‐related morbidity. Results: We examined 254 groins in 129 patients by SNB combined with FDG PET / CT . The median (interquartile range, IQR ) follow‐up of survivors was 23 (14–35) months. Of 201 LN ‐negative groins, two were false negatives, and despite radio‐chemotherapy treatment, both patients died from penile cancer. Four of 23 radiotracer‐silent groins, had a FDG PET / CT ‐positive LN s and were surgically explored. In one of four of the explored groins, a positive LN was found. Combined FDG PET / CT ‐ SNB sensitivity was 94.4% (95% confidence interval [ CI ] 81–99%) per groin. The false‐negative rate was 5.6% (95% CI 1–19%) per groin. In 15 patients (11.6%) there were 25 SNB ‐related complications of Clavien–Dindo grades I– III a. The only Clavien–Dindo III a complication was an inguinal lymphocele treated by aspiration. Conclusion: In this study, we present a favourable SNB false‐negative rate of 5.6% in a national cohort of clinically LN ‐negative patients with invasive PSCC with a pre‐ SNB FDG PET / CT scan. The combination of FDG PET / CT and SNB seems to be a promising diagnostic approach. Even so, a false‐negative SNB was fatal in two of two cases and we are determined to continue the development of our SNB technique. The SNB ‐related morbidity was limited.


  • DaPeCa-2: Implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process – A comparative before-and-after study in a tertiary referral centre in Denmark

    by Jakob Kristian Jakobsen, Jørgen Bjerggaard Jensen

    DaPeCa-2: Implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process – A comparative before-and-after study in a tertiary referral centre in Denmark. . ???aop.label???. doi: 10.3109/21681805.2015.1077472


  • A urologist’s contemporary guide to penile cancer

    by Jakob Kristian Jakobsen

    Few urologists deal with penile cancer on a daily basis. Owing to the rarity of the disease and its diversity in presentation, clinical experience accumulates slowly and new paradigms spread sporadically. This review provides a concise update on the background, clinical features and multidisciplinary management strategies of penile cancer. The evidence base of penile cancer management recommendations is devoid of randomized controlled trials and relies mainly on retrospective cohort studies from single institutions. In recent years, international multicentre collaboration has increased the quality of evidence. Larger study cohorts allow researchers to engage in subgroup analysis of patients with poor prognosis, of which the literature so far has been scarce. Comprehensive evidence-based guidelines are available through the European Association of Urology. This review highlights the importance of early and minimally invasive regional lymph-node staging of all patients of stage T1G2 or higher, and underlines the therapeutic potential of inguinal lymph-node dissection in lymph-node positive patients. A discussion of the oncological safety of current trends towards more phallus-sparing treatment techniques emphasizes the importance of proper case selection, thorough patient information, consequent follow-up and the possibility of a reconstructive procedure after organ-sparing ablative penile surgery. The aetiological role of human papilloma virus (HPV) is touched upon and the evidence for circumcision and HPV vaccination of boys is briefly weighed. The value of multidisciplinary treatment of advanced penile cancer is underlined and the role of chemotherapy, radiotherapy and radiochemotherapy is discussed. Finally, the perspectives for hybrid tracer sentinel node, robot-assisted lymph-node surgery and targeted therapies are addressed.


  • DaPeCa‐1: diagnostic accuracy of sentinel lymph node biopsy in 222 patients with penile cancer at four tertiary referral centres – a national study from Denmark

    by Jakob K. Jakobsen, Kim P. Krarup, Peter Sommer, Henrik Nerstrøm, Vivi Bakholdt, Jens A. Sørensen, Kasper Ø. Olsen, Bjarne Kromann‐Andersen, Birgitte G. Toft, Søren Høyer, et al.

    Objectives: To estimate the diagnostic accuracy of sentinel lymph node biopsy ( SNB ) in patients with penile cancer and assess SNB complications in a national multicentre setting. Patients and methods: Retrospectively data were collected from records in four university centres by one medical doctor covering all SNB s performed in Denmark between 1 January 2000 and 31 December 2010. Patients had either impalpable lymph nodes ( LN s) in one or both groins, or had a palpable inguinal mass from which aspiration cytology failed to reveal malignancy. Patients were injected with nanocolloid technetium and had a scintigram recorded before the SNB . The primary endpoint was LN recurrence on follow‐up. The secondary endpoint was complications after SNB . Diagnostic accuracy was computed. Results: In all, 409 groins in 222 patients were examined by SNB . The median (interquartile range) follow‐up of patients who survived was 6.6 (5–10) years. Of 343 negative groins, eight were false negatives. The sensitivity was 89.2% (95% confidence interval 79.8–95.2%) per groin. Interestingly, four of 67 T1G1 patients had a positive SNB . In all, 28 of 222 (13%) patients had complications of Clavien‐Dindo grade I– III a. Conclusion: Penile cancer SNB with a close follow‐up stages LN involvement reliably and has few complications in a national multicentre setting. Inguinal LN dissection was avoided in 76% of patients.